Zentalis Pharmaceuticals (NasdaqGM:ZNTL) 2026 Conference February 11, 2026 03:30 PM ET Company ParticipantsIngmar Bruns - CMOJulie Eastland - President and CEOConference Call ParticipantsMichael Schmidt - Senior Biotech AnalystMichael SchmidtKicking off the next fireside chat here. My name is Michael Schmidt, Senior Biotech Analyst with Guggenheim, and I'm really happy to welcome, Julie Eastland, President and CEO of Zentalis, and she's joined by, Ingmar Bruns, Chief Medical Officer. Welcome. Thanks for joi ...

February 11, 2026 Investor Presentation Q4 FY 2025 ©2026 Fastly, Inc. Fastly Q4 2025 Earnings Investor Deck (2/11/2026) 2 Investment highlights Clear market leader with differentiated technology Unified platform centered on innovation Large and growing addressable market Internet and AI trends driving significant opportunity Mission-critical platform vital for customer operations Multiple ways to accelerate and sustain growth ©2026 Fastly, Inc. Fastly Q4 2025 Earnings Investor Deck (2/11/2026) Forward Looki ...

Celldex Therapeutics (NasdaqCM:CLDX) 2026 Conference February 11, 2026 03:30 PM ET Company ParticipantsAnthony S. Marucci - President and CEODiane Young - CMOTibor Keler - Chief Scientific OfficerConference Call ParticipantsYatin Suneja - Biotech AnalystYatin SunejaEveryone, welcome to Guggenheim Emerging Outlook Biotech Summit 2026. My name is Yatin Suneja, one of the biotech analysts here at the firm. My pleasure to introduce my next presenting company, Celldex Therapeutics. From the company, we have thre ...

Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q4 and Year-End 2025 Earnings Presentation February 1 1, 2026 Safe Harbor and Forward-Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our produc ...

Q2 Fiscal Year 2026 © 2026 Cisco and/or its affiliates. All rights reserved. Cisco Confidential Business Momentum & Key Trends Conference Call February 11, 2026 Forward-Looking Statements This presentation contains projections and other forward-looking statements regarding future events or the future financial performance of Cisco, including future operating results. These projections and statements are only predictions. Actual events or results may differ materially from those in the projections or other f ...

Investor Presentation. Q4 2025 Safe Harbor This presentation includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding management's expectations of future financial and operational performance and operational expenditures, expected growth, foreign currency movement, and business outlook, including our financial guidance for the first fiscal quarter of and full year 2026 and our long-term financial framework; state ...

AnaptysBio Conference Call Summary Company Overview - **Company**: AnaptysBio (NasdaqGS:ANAB) - **Event**: Guggenheim Emerging Outlook Biotech Summit 2026 - **Date**: February 11, 2026 Key Points Company Separation - AnaptysBio is in the process of separating its biopharma operations from its core royalty portfolio, targeting a Q2 2026 separation date [4] - The biopharma business will include three clinical stage programs: - Rosnilimab (completed Phase 2b study in RA, moving to Phase 3) [5] - CD122 program (two studies: one ongoing in celiac disease, one initiating in EOE) [5] - ANB101 (BDCA2 modulator, ongoing Phase 1 trial) [5] - The new biopharma entity will be publicly traded and capitalized adequately to support its clinical trials [5] Royalty Portfolio - The royalty business is anchored on two programs: - Jemperli (royalty from GSK, projected to generate $1.8 billion in revenue this year) [6] - Imsidolimab (outlicensed to Vanda, seeking accelerated approval) [6] - Jemperli's growth rate is expected to remain strong, with significant market share capture anticipated due to its survival data compared to competitors [8][10] - GSK's guidance suggests potential peak sales of over $2.7 billion, with a long runway for growth [14] Clinical Programs - **Rosnilimab**: - End-of-phase 2 meeting with the FDA scheduled to define the size of the Phase 3 program [138] - Focus on securing funding for the Phase 3 program while prioritizing the separation of the companies [146] - **CD122 Program**: - Differentiated mechanism targeting both IL-15 and IL-2 signaling, with applications in celiac disease and eosinophilic esophagitis (EOE) [57][68] - Ongoing studies in celiac disease aim to demonstrate therapeutic benefits for patients with gluten exposure [97][103] - EOE studies will focus on both eosinophil reduction and symptomatic impact, with data expected in 2027 [114] - **ANB101 (BDCA2 Modulator)**: - Competing with a first-generation BDCA2 in Phase 3 trials by Biogen, with AnaptysBio's drug showing a differentiated depletion profile [121][125] Market Potential - Celiac disease has over 2 million patients in the U.S., with approximately 250,000 non-compliant to a gluten-free diet, representing a significant market opportunity [97] - The EOE market is also substantial, with a need for effective treatments beyond existing options [114] Financial Considerations - AnaptysBio has $310 million in cash at the beginning of the year, sufficient to fund operations into 2028 if allocated to the biopharma business [51] - The company has been actively repurchasing stock, indicating confidence in its valuation and future prospects [46] Regulatory Environment - The company is navigating ongoing litigation related to Jemperli, but it does not impact the planned separation of the biopharma business [16][18] Conclusion - AnaptysBio is positioned for significant growth through its clinical programs and the separation of its business units, with a strong focus on capitalizing on its royalty portfolio and advancing its biopharma pipeline. The upcoming data releases and regulatory meetings will be critical in shaping the company's future trajectory.

Profitable Production Growth Creating Long-Term Value FEBRUARY | 2026 Birchcliff's 100% owned and operated Pouce Coupe Gas Plant Corporate Presentation This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. For further information regarding the forward-looking statements and forward-looking information contained herein, see "Advisories – Forward-Looking Statements". With respect to the disclosure of Birchcliff's production cont ...

QuantumScape Corp (NASDAQ: QS) Investor Presentation February 2026 QUANTUMSCAPE CONFIDENTIAL Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws based on management's current expectations, assumptions, and available information about future events as of the date of this letter. All statements, other than historical facts, including those about the Company's anticipated commercial and operational milestones, financial outlook, a ...

Voyager Technologies (NYSE:VOYG) FY Conference February 11, 2026 02:50 PM ET Company ParticipantsAdi Padva - CFOWallace Laughrey - Chief Strategy OfficerConference Call ParticipantsGautam Khanna - Managing Director and Senior Equity Research AnalystGautam KhannaWell, thank you guys. Really appreciate, all of you for attending the TD Cowen Aerospace and Defense Conference. My name is Gautam Khanna. I'm the TD Cowen Aerospace and Defense Research Analyst. We're very privileged to have with us representatives ...